386 filings
Page 3 of 20
D
xpt7yhau1o4
19 Oct 23
$5.03 mm in options, sold $5.03 mm, 1 investor
4:06pm
6-K
ci6t27 g0
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
9kbgswaud13bqshuf8
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
cbowg91
16 Oct 23
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
4:01pm
6-K
j3bvzqm3tf6d94 er
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
pm7d7f
3 Oct 23
SciSparc Granted European Patent for its Core Technology
7:35am
6-K
vi797tnh4m
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
agw10epw9ynsr3
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
xa3nx
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
vb54uo6hjk3dvcdvc
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
ux9trjq9
18 Aug 23
Report of Foreign Private Issuer
4:01pm
6-K
8x4pad1ekbuddwne13di
14 Aug 23
Supplemental Proxy Statement
5:29pm
6-K
nd5exr778
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
424B5
w2m1hmhry0xy t8lb
14 Aug 23
Prospectus supplement for primary offering
9:14am
424B3
n60cxf9w9wc
10 Aug 23
Prospectus supplement
6:32am
6-K
agtw4rd2
9 Aug 23
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
7:30pm
424B3
dtrxzumzwrmytlhnc0
9 Aug 23
Prospectus supplement
4:01pm
6-K
3pqk5zfmv
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
6inxvr cytq
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
5q4 0apjuaksvyeus19r
11 Jul 23
Report of Foreign Private Issuer
4:16pm